Somewhat Positive Press Coverage Somewhat Unlikely to Affect Wave Life Sciences (WVE) Share Price

Press coverage about Wave Life Sciences (NASDAQ:WVE) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Wave Life Sciences earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.6528028131905 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Wave Life Sciences (NASDAQ WVE) opened at $38.35 on Monday. The company has a current ratio of 11.50, a quick ratio of 11.50 and a debt-to-equity ratio of 0.01. Wave Life Sciences has a 52-week low of $15.15 and a 52-week high of $39.70.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.03. The business had revenue of $0.68 million during the quarter, compared to analyst estimates of $0.77 million. Wave Life Sciences had a negative net margin of 3,338.68% and a negative return on equity of 59.52%. research analysts expect that Wave Life Sciences will post -3.76 EPS for the current fiscal year.

A number of research firms have commented on WVE. BidaskClub raised shares of Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 2nd. Leerink Swann reaffirmed an “outperform” rating and set a $53.00 price objective (up from $42.00) on shares of Wave Life Sciences in a research note on Wednesday, November 15th. Mizuho set a $34.00 price objective on shares of Wave Life Sciences and gave the company a “buy” rating in a research note on Saturday, October 21st. Finally, Zacks Investment Research raised shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $41.60.

In related news, insider Chandra Vargeese sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $35.00, for a total transaction of $52,500.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ra Capital Management, Llc acquired 423,398 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The shares were acquired at an average cost of $23.34 per share, for a total transaction of $9,882,109.32. The disclosure for this purchase can be found here. 53.00% of the stock is owned by corporate insiders.

WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Wave Life Sciences (WVE) Share Price” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/12/18/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-wave-life-sciences-wve-share-price.html.

Wave Life Sciences Company Profile

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Insider Buying and Selling by Quarter for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply